Form 4: Phathom Pharmaceuticals CFO and CBO, Molly Henderson, Reports Acquisition of Shares and Stock Options

Molly Henderson, CFO and CBO of Phathom Pharmaceuticals, reports the acquisition of 72,000 shares of common stock and 50,000 stock options.

Summary

• On February 27, 2025, Molly Henderson, the CFO and CBO of Phathom Pharmaceuticals, acquired 72,000 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs vest in three equal installments on the anniversaries of February 27, 2025, contingent upon continued service.
• Each RSU represents the right to receive one share of Phathom Pharmaceuticals common stock.
• Henderson also acquired 50,000 stock options with an exercise price of $5.76.
• These options vest 25% on February 27, 2026, and the remainder in equal monthly installments over the subsequent three years, also contingent upon continued service.
• Following these transactions, Henderson directly owns 165,546 shares of common stock and indirectly owns 1,911.27 shares through a 401(k).
• She also directly owns 50,000 stock options.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing detailing stock transactions by an officer. The acquisition of shares and options could be seen as a positive signal, but it's not definitive.

Positives

• The acquisition of shares and stock options by a key executive could be interpreted as a sign of confidence in the company's future prospects.

Future Outlook

The vesting schedules for both the RSUs and stock options are contingent upon the reporting person's continued service to the company.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transactions reported may influence investor perception of the company.

Key Dates